2-Ethoxy Ethyl Methacrylate (EEMA) is a monomer used in the synthesis of polymers. It is a colorless liquid with a mild odor. EEMA is synthesized by the reaction of methacrylic acid with 2-ethoxyethanol in the presence of a catalyst. EEMA is known for its ability to form polymers with good adhesion, flexibility, and resistance to chemicals. These properties make EEMA valuable in various applications, including adhesives, coatings, and sealants. The study of EEMA focuses on its polymerization behavior, the properties of its polymers, and the potential applications of these polymers. EEMA is also being studied for its potential use in biomedical applications, such as drug delivery and tissue engineering.'
2-ethoxy ethyl methacrylate: RN given refers to monomer
ID Source | ID |
---|---|
PubMed CID | 71404 |
CHEMBL ID | 1414186 |
SCHEMBL ID | 36524 |
MeSH ID | M0093426 |
Synonym |
---|
unii-5q6xr4mr8e |
5q6xr4mr8e , |
2-propenoic acid, 2-methyl-, 2-ethoxyethyl ester |
2-ethoxyethyl methacrylate |
ethoxyethyl methacrylate |
nsc-24162 |
nsc24162 |
2370-63-0 |
methacrylic acid, 2-ethoxyethyl ester |
2-(ethyloxy)ethyl 2-methylprop-2-enoate |
NCGC00166254-01 |
2-ethoxyethyl methacrylate, contains 100 ppm hydroquinone monomethyl ether as inhibitor, 99% |
nsc 24162 |
2-ethoxy ethyl methacrylate |
einecs 219-135-3 |
51289-08-8 |
2-ethoxyethyl 2-methylprop-2-enoate |
methacrylic acid 2-ethoxyethyl ester |
ethylene glycol monoethyl ether methacrylate |
M1251 |
NCGC00260360-01 |
cas-2370-63-0 |
dtxcid202186 |
dtxsid1022186 , |
tox21_202814 |
AKOS015912731 |
ethoxyethyl methacrylate [inci] |
.beta.-ethoxyethyl methacrylate |
acryester et |
ethanol, 2-ethoxy-, methacrylate |
SCHEMBL36524 |
2-ethoxyethyl 2-methylacrylate # |
W-109774 |
CHEMBL1414186 |
mfcd00009249 |
2-ethoxyethyl methacrylate, (stabilized with mehq) |
2-ethoxyethyl methacrylate (stabilized with mehq) |
FT-0720731 |
ethoxyethylmethacrylate |
Q27262728 |
BS-52221 |
STARBLD0019598 |
CAA37063 |
F71270 |
Excerpt | Reference | Relevance |
---|---|---|
" The lack of toxicity in these specimens suggests that residual contents of inhibitor and initiator are too low to cause toxic effects on choroidal fibroblasts." | ( Cytotoxic effects of residual chemicals from polymeric biomaterials for artificial soft intraocular lenses. Barrett, GD; Chirila, TV; Constable, IJ; Thompson, DE; Walker, LN, 1991) | 0.28 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.7727 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 42.7334 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 1.5418 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 54.7044 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 49.2000 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 101.2060 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 125.8920 | 0.0100 | 39.5371 | 1,122.0200 | AID1479 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 54.7044 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 54.7044 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.57) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |